Investors

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Calendar


May 3, 2024 - Interim Report Q1 2024 (7:00am CEST)
May 6, 2024 - Annual General Meeting
August 22, 2024 - Interim Report Q2 2024 (7:00am CEST)
November 8, 2024 - Interim Report Q3 2024 (7:00am CET)

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com